PROGEN acquires EuroProxima’s research antibodies

Home  >>  News  >>  PROGEN acquires EuroProxima’s research antibodies

PROGEN acquires EuroProxima’s research antibodies

On October 9, 2017, Posted by , In News, With Comments Off on PROGEN acquires EuroProxima’s research antibodies

PROGEN Biotechnik GmbH expands portfolio in the cell biology market

Heidelberg, 05.10.2017 – PROGEN Biotechnik GmbH, established manufacturer of premium antibodies, has recently acquired the research antibody line of the Dutch company EuroProxima B.V., a global provider of immunobiological test systems. The deal encompasses about 190 products that supplement PROGEN’s portfolio of proprietary immunochemicals.

The purchase is part of PROGEN’s expansion in the cell biology research antibody market. Dr. Sven Kuhlendahl, General Manager of PROGEN: “It is a pleasure to announce the integration of EuroProxima’s high-class antibodies into our own portfolio of over 500 antibodies. The addition of keratin and hormone antibodies in particular complement our product range substantially. We are now in an excellent position to serve research laboratories worldwide with a broad variety of immunochemical tools.”

PROGEN reaches out to potential partners in its endeavor to further expand its research reagents business. This includes monoclonal and recombinant antibodies as well as immunochemical tests supporting the validity of cell biology experiments. PROGEN serves specifically to today’s urgent customer need for high quality and reliability.

Standing for premium quality, PROGEN’s newly acquired antibodies will adhere to the highest standards that warrant dependable specificity and reproducibility. The acquired product line is already available in the company’s web shop (


Since 1983, PROGEN has been an established manufacturer and supplier of premium antibodies, in vitro diagnostics, and reagents for the global life science research community. While PROGEN’s antibodies are among the most published antibodies in biomedical and cell biology literature, its ELISA kits aim at niche markets. Building on its core-competency in immunochemistry, the company has expanded its collaborations and business in recent years to access new research markets with innovative immunological products. The activities of the DIN EN ISO 13485 certified company focus on the development of ELISA tests for the determination of adeno-associated virus titers in gene therapy research and development. Since 2012, PROGEN has been a 100% subsidiary of the R-Biopharm AG.


Katja Betts

Head of Marketing

Phone: +49 6221 8278-16



Comments are closed.